TY - JOUR T1 - Temporal Variations in Seroprevalence of SARS-CoV-2 Infections by Race and Ethnicity in Arkansas JF - medRxiv DO - 10.1101/2021.07.15.21260213 SP - 2021.07.15.21260213 AU - Joshua L. Kennedy AU - J. Craig Forrest AU - Sean G. Young AU - Benjamin Amick AU - Mark Williams AU - Laura James AU - Jessica Snowden AU - Victor M. Cardenas AU - Danielle Boothe AU - Catherine Kirkpatrick AU - Zeel Modi AU - Katherine Caid AU - Shana Owens AU - Marianne Kouassi AU - Ryan Mann AU - Claire Putt AU - Katherine Irish-Clardy AU - Michael Macechko AU - Ronald K. Brimberry AU - Wendy N. Nembhard AU - Ruofei Du AU - Jing Jin AU - Namvar Zohoori AU - Atul Kothari AU - Hoda Hagrass AU - Ericka Olgaard AU - Karl W. Boehme Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/19/2021.07.15.21260213.abstract N2 - Objective Our objective is to estimate CoV-2 infection rates in a rural state using seroprevalence of antibodies to CoV-2 as an indicator of infection.Study Design and Setting This is a single-site study within an academic center and regional programs within the state of Arkansas. We obtained residual serum samples from a convenience sample of adults who were outpatients and came to the hospital or regional clinic for non-COVID-related reasons. We collected remnant in three time periods (August 15 to September 5, September 12 to October 24, and November 7 to December 19).Results In 2020, the overall age, gender, and race standardized prevalence of CoV-2 antibodies was 2.6% (August to September), 4.1% (September to October), and 7.4% (November to December). There was no difference in seroprevalence between urban compared to rural areas. Positive tests were not uniformly distributed across racial and ethnic minorities. Higher seroprevalence rates were found in Hispanics and Blacks or African Americans compared to whites across all time periods.Conclusions In a state with a large rural population, 2.6-7.4% of people experienced CoV-2 infection by December 2020. Blacks and Hispanics had disproportionately higher rates of CoV-2 infections than whites.Key findings In this prospective convenience sampling of remnant sera, we found increasing seroprevalence from 2.6% to 7.4% (August 2020 to December 2020). Higher seroprevalence rates were found in Hispanics and Blacks or African Americans compared to whites across all time periods, and no difference was determined between those individuals from rural or urban areas.What this adds to what is known In a largely rural population, Blacks and Hispanics had disproportionately higher rates of CoV-2 infections than whites, and these populations need to be studied further regarding outcomes.What is the implication?There are health disparities that exist regarding CoV-2 infections, and we should target vaccination information and education to these groups.Highlights- SARS-CoV-2 infections increased from 2.6% to 7.4% from August to December 2020.- Higher seroprevalence was found in Hispanics and Blacks as compared to whites.- There was no difference in the seroprevalence in rural compared to urban areas.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the State of Arkansas facilitated through the CARES Act and the UAMS Time Sensitive COVID-19 Fund. The Translational Research Institute at UAMS provided support for logistics, coordination and implementation of this project, including provision of an honest broker, secure data storage and management through REDCap (NCATS/NIH 1 UL1 RR029884).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Arkansas for Medical Sciences Institutional Review Board provided approval for this study under IRB protocol 261232.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this manuscript is readily available for review with the proper approvals. ER -